Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 106,038

Document Document Title
WO/2015/095713A1
The invention provides enantiopure deuterium-enriched bupropion, pharmaceutical compositions, and methods of treating neurological disorders, movement disorders, cardiovascular disorders, metabolic disorders, and other disorders using en...  
WO/2015/090224A1
The present invention provides a compound of a general formula I, a stereomeride, pharmaceutically acceptable salt or a solvate thereof, a preparation method thereof, and usages in preparing medicines for preventing and/or treating disea...  
WO/2015/090209A1
Provided in the present invention are a general formula I compound, the isomers, pharmaceutically-acceptable salt or solvate thereof, and application thereof to manufacturing medicine for preventing and/or treating drug-resistant tumours...  
WO/2015/090223A1
Provided are extracellular matrix protein 1(ECM1) and fusion protein Fc-EcMI of the ECM1 and the Fc sequence, and also provided are cloning, construction and expression of the protein, and use of the protein in preparing a pharmaceutical...  
WO/2015/089599A1
The present invention relates to the method for preparing the anhydrous crystalline form of isoniazid-derived hydrazone (8-hydroxyquinoline-2-carboxaldehyde isonicotinoyl hydrazone), to the thus produced polymorph and to the use thereof ...  
WO/2015/091463A1
A compound of Formula (1) wherein R1 represents hydrogen, halo, a C1-C4 alkyl group, a C1-C4 alkylhalide group, a C1-C4 alkoxy-C2-C4 alkyl group, a C2-C4 alkenyl group, a C2-C4 alkynyl group or a C3- C7 cyclo alkyl group; R2 represents F...  
WO/2015/089664A1
A composition for therapy of a peripheral neuropathy disorder in a subject in need thereof. The composition comprises an effective amount of an agent selected from a group consisting of pirenzepine, oxybutynin, muscarinic toxin 7, a musc...  
WO/2015/090235A1
Provided herein are novel piperazine compounds and pharmaceutical compositions thereof comprising the piperazine compounds for inhibiting serotonin reuptake and/or acting as 5-HT1A receptor agonists. Also provided herein are methods for ...  
WO/2015/093503A1
 Provided is an adhesive patch that exhibits sufficiently high dexmedetomidine absorbency and little dermal irritation. The water-containing adhesive patch contains a water soluble polymer and dexmedetomidine or a salt thereof.  
WO/2015/091874A1
The invention relates to a pharmaceutical matrix tablet which can be administered orally once or twice per day with gastro-retentive controlled release of Baclofen.  
WO/2015/092009A1
The present invention relates to compounds having dual pharmacological activity towards both the sigma (σ) receptor, and the μ-opiod receptor and more particularly to piperazine compounds having this pharmacological activity, to proces...  
WO/2015/094670A1
The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the c...  
WO/2015/091833A1
The present invention relates to an opioid antagonist with κ- activity for use in treatment of depressive disorder with melancholic features. The invention further relates to the combination of an opioid antagonist with κ- activity and...  
WO/2015/091718A1
The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the prevention or treatment of attention deficit and/or hyperactivity in an individual.  
WO/2015/090394A1
Compositions comprising omega 3 fatty acids for use in the treatment, amelioration or prevention of various conditions, disorders, and diseases which involve damage to the nervous system, as the peripheral nervous system neuropathy and g...  
WO/2015/093933A1
The present invention relates to the use of kisspeptin and its agonist(s) to modulate serotonin. The invention may be used in the treatment of serotonin-linked conditions in the brain such as depression, fear, and anxiety. The invention ...  
WO/2015/091595A1
The present invention provides a compound of formula I' having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the pres...  
WO/2015/092592A1
The present invention provides novel 3,4-disubstituted-1 H-pyrrolo[2,3- Jb]pyridine derivatives and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof (I) wherein R...  
WO/2015/092538A1
A use of an extract or fraction, derivative or chemically synthesized or modified form of any one or more components of Ophiocordyceps or a genetically modified or phenotypically adapted strain thereof in manufacture of a medicament for ...  
WO/2015/090599A1
The invention relates to pyrrole carboxamides bearing a fluoromethyl- moiety as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or...  
WO/2015/091931A1
The present invention relates to novel substituted oxindole derivatives of formula (I) wherein the variables are as defined in the claims and description; to pharmaceutical compositions comprising them, and to their use for treatment of ...  
WO/2015/095644A1
Disclosed herein are compositions containing an opioid antagonist such as naloxone and one or more pharmaceutically acceptable excipients. The compositions may be used for intranasal delivery of Naloxone for the treatment of, for example...  
WO/2015/089530A1
Disclosed is an extended-release oral dosage form comprising morphine or a physiologically acceptable salt thereof and naloxone or a physiologically acceptable salt thereof for oral opioid substitution therapy. The dosage form contains 0...  
WO/2015/091939A1
The present invention relates to compounds having dual pharmacological activity towards both the sigma receptor and the mu-opioid receptor, and more particularly to piperidine compounds having this pharmacological activity, to processes ...  
WO/2015/091505A1
The invention refers to a synergistic combination comprising a Sigma ligand of general formula (I), and a Gabapentinoid, a medicament comprising said active substance combination, and the use of said active substance combination for the ...  
WO/2015/087094A1
The invention relates to novel arylalkenylpropargylamine derivatives of general formula (I) or enantiomers or diastereomers thereof or salts, optionally pharmaceutically acceptable salts, or solvates of any of these. The compounds can be...  
WO/2015/089337A1
The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.  
WO/2015/088000A1
The objective of the present invention is to provide a novel low molecular weight compound which exhibits an orexin agonist activity and is expected to be useful as an excellent therapeutic or preventive agent for narcolepsy. The present...  
WO/2015/088288A1
The present invention relates to a method for promoting the generation of a stem cell-derived exosome by using thrombin. The method according to the present invention has a remarkable effect of promoting the generation of a stem cell-der...  
WO/2015/088271A1
The present invention relates to a pharmaceutical composition for treating or preventing epilepsy containing a sulfamate derivative compound and/or pharmaceutically acceptable salt thereof as an active ingredient. Furthermore, the presen...  
WO/2015/089182A1
The present patent application discloses at least the compounds according to Formula 1 shown below, or pharmaceutically acceptable salts thereof, wherein ringj B,n, JD, J,0, X, X1, J, RC, and W are as defined herein. These compounds are ...  
WO/2015/087865A1
Provided is a novel compound which has excellent Aβ aggregation inhibition effects and is useful as a drug. The present invention is an amide compound represented by general formula (1) or a salt thereof. (In the formula, Z is CH or N, ...  
WO/2015/088272A1
The present invention relates to sulfamate derivative compounds and a composition for treating and/or alleviating pain containing the sulfamate derivative compounds or a pharmaceutically acceptable salt thereof as an active ingredient. M...  
WO/2015/086789A1
The invention relates to modified sweet whey protein (MSWP) for promoting the establishment of healthy and normal cognitive function in young mammals. In particular, the invention relates to the use of MSWP for promoting development of t...  
WO/2015/087017A1
The invention relates to a novel use of a pharmaceutical composition comprising at least one methyl cyclodextrin having a degree of molar substitution (MS) of between 0.05 and 1.5 in the treatment and/or prevention of diseases that can b...  
WO/2015/089416A1
Methods for treating a patient suffering from neural cell injury, the method comprising administering to the patient an effective amount of a HIF prolyl-4-hydroxylase inhibiting compound having the following general formula (1) wherein R...  
WO/2015/085860A1
Disclosed are a heterocyclic hydroxamic acid compound having a general formula I, and pharmaceutically acceptable acid or alkali salts or stereoisomers thereof. The present compound and pharmaceutically acceptable salts thereof effective...  
WO/2015/087853A1
Provided are: a crystal form of (-)-(2-{[3-(5-fluoropyridin-2-yl)-1H-pyrazol-1-yl]methyl}-1, 3-oxazinan-3-yl)[5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]me thanone, said crystal form being stable in the environment of usage thereof as a me...  
WO/2015/088915A1
Methods and compositions are provided for treating a subject for aging-associated conditions, e.g., cognitive impairment conditions. Aspects of the methods include administering a young plasma-comprising blood product to an individual in...  
WO/2015/087926A1
A laminate-type patch which is provided with a support layer, a drug reservoir layer and a pressure-sensitive adhesive layer, wherein: the drug reservoir layer contains at least one drug selected from the group consisting of rivastigmine...  
WO/2015/087993A1
A compound represented by formula (I) or a pharmaceutically acceptable salt thereof is a novel compound or a pharmaceutically acceptable salt thereof which has an antagonistic activity on orexin (OX) receptors and is therefore useful for...  
WO/2015/089327A1
The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.  
WO/2015/086836A1
The present invention claims a chromone derivative and pharmaceutical compositions and combinations comprising a least the said derivative, which is a dopamine D3 receptor antagonist, for their use for the treatment of autism spectrum di...  
WO/2015/087016A1
The invention relates to a novel use of a pharmaceutical composition comprising at least one methyl cyclodextrin having a molar substitution (MS) degree of between 0.05 and 1.5 in the treatment and/or prevention of diseases that can be t...  
WO/2015/089420A1
A controlled release dosage form containing monomcthyl fumarate, a compound that can be metabolized into monomcthyl fumarate in vivo, or a pharmaceutically acceptable salt thereof or combinations thereof, wherein the monomcthyl fumarate,...  
WO/2015/088273A1
The present invention relates to sulfamate derivative compounds and a composition for treating and/or alleviating pain containing the sulfamate derivative compounds or a pharmaceutically acceptable salt thereof as an active ingredient. M...  
WO/2015/085739A1
A multilayer solid pharmaceutical dosage form, comprising a core having active ingredients, a first layer of sustained release coating covering the core, a drug layer having active ingredients and covering the first layer of sustained re...  
WO/2015/089349A1
This invention provides methods and pharmaceutical compositions that can treat neuroinflammatory disease by reducing the production of pyrophosphate intermediates produced during the biosynthesis of isoprenoids. The pyrophosphate compoun...  
WO/2015/088706A1
A composition and method for enhancing brain development in a pediatric subject, the method including administering to the pediatric subject a nutritional composition comprising at least about 0.08 g/100 kcal of stearidonic acid.  
WO/2015/088286A1
The present invention relates to a pharmaceutical composition for treating cerebrovascular diseases, containing a stem cell-derived exosome as an active ingredient. The stem cell-derived exosome according to the present invention has rem...  

Matches 101 - 150 out of 106,038